RNA Design. By Intelligence.

THE TEAM

A team of seasoned operatives joined forces with leading investigators in RNA biology and AI to build a category defining RNA design company.

Nazli Azimi

Co-Founder & CEO

Sasan Amini

Co-Founder

Hani Goodarzi

Scientific Co-Founder

Kevin Kipp

Sr. Director of Preclinical and Translational Research

Kian Yousefi

Director of Translational Research, Founding Scientist

Timo Hagen

Director of RNA Research, Founding Scientist

Amir Momen-Roknabadi

Director of AI

Amir Moarefi

Director of Business Development

With more than two decades of research, Therna’s founders are at the forefront of regulatory RNA biology, authoring several acclaimed publications.

IN THE PRESS:

THE MODEL

Therna is pioneering a new era of programmable RNA therapeutics by integrating deep RNA biology with generative AI.

Our platform explores RNA sequence space to express, silence, or fine tune genes. It can design custom mRNAs with coveted therapeutic properties and identify target regions of mRNA for optimal ASO/siRNA design.

THE PROCESS

LAB IN THE LOOP

LAB IN THE LOOP

Our iterative pipeline seamlessly combines biology and computation: AI generates novel RNA sequences, lab experiments validate them, and results are used to retrain the model, enhancing its predictive capabilities.

THE APPLICATIONS

Therna’s proprietary generative RNA design platform marks a significant breakthrough in biotech innovation, enabling rapid and precise creation of custom RNA-based medicines. By dramatically accelerating the design cycle and unlocking programmable drug properties, our platform is deigned to address diseases previously out of reach for traditional modalities. This technology positions Therna at the forefront of a new era in medicine—one with vast commercial potential across multiple therapeutic areas.